<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03522935</url>
  </required_header>
  <id_info>
    <org_study_id>42336</org_study_id>
    <nct_id>NCT03522935</nct_id>
  </id_info>
  <brief_title>Subcutaneous Elafin in Healthy Subjects</brief_title>
  <official_title>Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roham T. Zamanian</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SRI International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate&#xD;
      the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult&#xD;
      subjects. The purpose of this study is to assess Elafin that is being developed for treatment&#xD;
      of PAH. Elafin inhibits elastase, an enzyme that is increased in pulmonary hypertension and&#xD;
      is a major factor in the development of PAH. Elafin will be administered subcutaneously daily&#xD;
      for 7 days in normal healthy subjects followed over a 28 day time period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be a total of up to 30 subjects randomly assigned to 5 groups with 6 subjects in&#xD;
      each group. One subject in each group will be assigned to placebo drug and 5 subjects to&#xD;
      active drug. Subjects in each group will receive a single daily dose of Elafin/Placebo for&#xD;
      total of 7 days. There will be ascending doses across groups. Groups receiving a higher dose&#xD;
      will only do so after the previous group has completed dosing (i.e., 7 days). Each subject&#xD;
      will be followed over a 28 day time period.&#xD;
&#xD;
      An interim trial analysis will occur after completion of the 2nd cohort in order for the&#xD;
      research team to review PK and safety data to determine modification (if needed) of dosing&#xD;
      strategy for groups 3-5. The study is also designed to absorb a de-escalation strategy. If&#xD;
      the protocol requires a lowering of dose from the initial dosing, a new group will be&#xD;
      assigned a low-dose subcutaneous Elafin regimen.&#xD;
&#xD;
      The study will conclude at any dose that produces clinically significant adverse effects and&#xD;
      identified as Maximum Tolerated Dose (MTD).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2019</start_date>
  <completion_date type="Actual">November 18, 2020</completion_date>
  <primary_completion_date type="Actual">October 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events in healthy controls.</measure>
    <time_frame>28 day time period</time_frame>
    <description>Safety and tolerability will be determined on the basis of adverse events reported and the severity of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: AUC0-last</measure>
    <time_frame>28 day time period</time_frame>
    <description>AUC0-last: Area under the concentration time-curve to the last concentration above the lower limit of quantitation (after final dose consumed)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Cmax</measure>
    <time_frame>28 day time period</time_frame>
    <description>Cmax: Maximum observed concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Tmax</measure>
    <time_frame>28 day time period</time_frame>
    <description>Tmax: Time of maximum observed concentration</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: Ke</measure>
    <time_frame>28 day time period</time_frame>
    <description>Ke: Elimination rate constant</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: AUC0-inf</measure>
    <time_frame>28 day time period</time_frame>
    <description>AUC0-inf: Area under the concentration time-curve extrapolated to infinit</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: t½</measure>
    <time_frame>28 day time period</time_frame>
    <description>t½: Terminal elimination half-life</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: CL/F</measure>
    <time_frame>28 day time period</time_frame>
    <description>CL/F: Apparent total clearance of the drug from plasma after oral administration</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic/pharmacodynamic (PK/PD) and immunogenicity parameters in blood sample: V/F</measure>
    <time_frame>28 day time period</time_frame>
    <description>V/F: Oral volume of distribution</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Elafin 0.03 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will be administered with 0.03 mg/kg of Elafin subcutaneously once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elafin 0.06 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will be administered with 0.06 mg/kg of Elafin subcutaneously once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elafin 0.10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will be administered with 0.10 mg/kg of Elafin subcutaneously once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elafin 0.15 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will be administered with 0.15 mg/kg of Elafin subcutaneously once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elafin 0.18 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 subjects will be administered with 0.18 mg/kg of Elafin subcutaneously once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Drug</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 subjects will be administered with placebo drug subcutaneously once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elafin</intervention_name>
    <description>Elafin subcutaneous.</description>
    <arm_group_label>Elafin 0.03 mg/kg</arm_group_label>
    <arm_group_label>Elafin 0.06 mg/kg</arm_group_label>
    <arm_group_label>Elafin 0.10 mg/kg</arm_group_label>
    <arm_group_label>Elafin 0.15 mg/kg</arm_group_label>
    <arm_group_label>Elafin 0.18 mg/kg</arm_group_label>
    <other_name>Tiprelestat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo subcutaneous.</description>
    <arm_group_label>Placebo Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject will be eligible only if all of the following criteria apply:&#xD;
&#xD;
          1. Male or female, 18 - 55 years of age&#xD;
&#xD;
          2. No history or clinically relevant cardiovascular, renal, gastrointestinal, hepatic,&#xD;
             metabolic, endocrine, neurological, or psychiatric abnormalities and is in general&#xD;
             good health at screening examination.&#xD;
&#xD;
          3. Normal or clinically acceptable ECG&#xD;
&#xD;
          4. Normal blood pressure (systolic: 90 - 140 mmHg; diastolic: 50 - 90 mmHg) and heart&#xD;
             rate (45 - 100 bpm)&#xD;
&#xD;
          5. Body mass index of 18.0 - 32.0 (kg/m2)&#xD;
&#xD;
          6. Ability to communicate well with the investigator and to comply with the requirements&#xD;
             of the entire study.&#xD;
&#xD;
          7. Informed consent.&#xD;
&#xD;
          8. Females of childbearing potential must use an acceptable form of contraception at time&#xD;
             of enrollment (and throughout the duration of study) including, but not limited to the&#xD;
             following:&#xD;
&#xD;
               1. Documentation of surgical sterilization (bilateral tubal ligation, hysterectomy)&#xD;
&#xD;
               2. Naturally postmenopausal (spontaneous cessation of menses) for at least 24&#xD;
                  consecutive months prior to dosing on Day -1 and with an FSH level at screening&#xD;
                  of ≥ 40 mIU/mL&#xD;
&#xD;
               3. Intrauterine Device (IUD) plus condom plus contraceptive sponge or foam or jelly&#xD;
&#xD;
               4. Condom plus contraceptive sponge or foam or jelly&#xD;
&#xD;
               5. Hormonal contraception (combination oral contraceptives, transdermal patch,&#xD;
                  injectables, implantables, or vaginal ring) *Subject is not of childbearing&#xD;
                  potential if the following criteria have been met:&#xD;
&#xD;
               1. Hysterectomy &gt; 1 month ago&#xD;
&#xD;
               2. Bilateral oophorectomy &gt; 1 month ago&#xD;
&#xD;
               3. 45-50 years old AND LMP ≥ 24 months ago and documented FSH &gt; 40mIU/mL&#xD;
&#xD;
          9. Males must agree to use a barrier method of birth control from 30 days before first&#xD;
             study drug administration until 90 days after last study drug administration.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        A subject will not be eligible if any of the following criteria apply:&#xD;
&#xD;
          1. Administration of any investigational drug 45 days prior to study enrollment.&#xD;
&#xD;
          2. Active participation in another interventional clinical trial.&#xD;
&#xD;
          3. Use of any prescription medication within 30 days (with exception to oral&#xD;
             contraceptives) or over-the-counter medication (OTC) within 7 days before first study&#xD;
             drug administration. Use of OTC medications may be permitted after day 1 visit until&#xD;
             end of study with approval of the protocol investigator.&#xD;
&#xD;
          4. Subject performed heavy physical exertion 2 days before eligibility assessment and&#xD;
             before admission into clinical research center.&#xD;
&#xD;
          5. Subject consumes more than 500 mL of beer/day or 250 mL of wine/day or 2 glasses of&#xD;
             liquor/day.&#xD;
&#xD;
          6. Subject has a history of chronic alcohol or drug abuse within the last 4 weeks.&#xD;
&#xD;
          7. Subject smokes more than 10 cigarettes per day or has done so within 6 months prior to&#xD;
             eligibility assessment.&#xD;
&#xD;
          8. Subject has a diet that deviates notably from the &quot;normal&quot; amounts of protein,&#xD;
             carbohydrate, and fat, as judged by the investigator (e.g., vegetarians or vegans).&#xD;
&#xD;
          9. Subject consumes more than 600 mg of caffeine/day (200 mL of coffee contain&#xD;
             approximately 100 mg of caffeine, 200 mL of black tea approximately 30 mg and 200 mL&#xD;
             of soda approximately 20 mg).&#xD;
&#xD;
         10. Subject has donated blood or had a comparable blood loss (&gt;400 mL) within the last 3&#xD;
             months prior to eligibility assessment or anemia defined by hematocrit value less than&#xD;
             30% at screening.&#xD;
&#xD;
         11. Subject has any clinically relevant abnormality in physical examination, vital signs&#xD;
             and electrocardiogram (ECG).&#xD;
&#xD;
         12. Serious adverse reaction or hypersensitivity to any drug.&#xD;
&#xD;
         13. Inability to communicate or co-operate due to a language problem, poor mental&#xD;
             development or impaired cerebral function.&#xD;
&#xD;
         14. Females who are lactating or at risk of pregnancy.&#xD;
&#xD;
         15. Presence of pain incurred by unknown causes.&#xD;
&#xD;
         16. History of asthma or other respiratory disease.&#xD;
&#xD;
         17. History of neurologic or neuromuscular disease.&#xD;
&#xD;
         18. History of hypotension, hypertension or cardiovascular disease.&#xD;
&#xD;
         19. History of gastrointestinal, hepatic, or renal disease and/or impairment.&#xD;
&#xD;
         20. Positive urine drug screen for drugs with a high potential for abuse and low&#xD;
             persistence in the urine.&#xD;
&#xD;
         21. Subject with active or history of malignancy, known Hepatitis B or C, or HIV.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roham Zamanian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Early Phase Research Unit (DEPRU)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>April 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Roham T. Zamanian</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Elafin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

